Next-Gen Therapies Directory
A structured index of advanced medicinal breakthroughs currently undergoing global regulatory transitions. Aamrit provides professional coordination and documentation support for patients requiring access to these therapies through lawful international pathways.
Retatrutide (LY3437943)
Multi-Receptor Peptide
A triple agonist peptide targeting GLP-1, GIP, and glucagon receptors for intensive metabolic and weight-management regulation.
AVAILABILITY: Not Approved in India (NPP Coordination Only)
Note: Documentation-led access coordination; not a pharmacy listing.
Compliance Notice: This directory is provided for informational purposes for healthcare professionals and patients. Aamrit facilitates professional coordination of documentation for special access; we do not dispense, stock, or recommend treatments. All access is subject to case-specific verification and prescription by a licensed treating physician.
Lifileucel (Amtagvi)
TIL Cell Therapy
Autologous tumor-infiltrating lymphocyte therapy designed for adult patients with unresectable or metastatic melanoma.
AVAILABILITY: FDA Approved (International Access Coordination Required)
Note: Documentation-led access coordination; not a pharmacy listing.
Casgevy (Exa-cel)
CRISPR Gene Editing
A CRISPR/Cas9-based gene-editing therapy for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia.
AVAILABILITY: Global Regulatory Pathway (Documentation Coordination Required)
Note: Documentation-led access coordination; not a pharmacy listing.